CEDAR KNOLLS,
N.J., Jan. 9, 2020
/PRNewswire/ -- MYOS RENS Technology, Inc. ("MYOS" or
"the Company") (NASDAQ: MYOS), an advanced nutrition company and
the owner of Fortetropin®, a proprietary
bioactive composition made from fertilized egg yolk that helps
build lean muscle, issued this shareholder letter highlighting its
2019 achievements and the Company's strategy going
forward.
Dear Fellow Shareholders,
As the Company moves forward it is
important to look back at the last few years. When I joined
MYOS, it was clear that we needed to take some significant risks
with uncertain outcomes in order to build an outstanding
company. No one likes uncertainty, not management, employees,
regulators, board members, or shareholders– especially
shareholders. However, for a small company to truly succeed it must
embrace uncertainty. There really is no other
choice.
Some of the major risks that we took included initiating a
human clinical study to assess the impact of Fortetropin® in older
adults, initiating a veterinary clinical study in dogs to assess
the impact of Fortetropin on recovery from orthopedic surgery,
launching the Yolked® brand for Sports
Nutrition and entering the animal health market. It gives me
great pleasure to see that these risks are now bearing fruit for
the Company and its shareholders.
We have now moved from a very uncertain future to a promising
future where we have products that are backed by clinical research
in three areas with explosive growth– Animal Health, Longevity and Sports
Nutrition.
Here are the key highlights of 2019:
- Completed randomized, double blind, placebo-controlled
clinical study at University of California,
Berkeley demonstrating that Fortetropin® increased the rate of
muscle protein synthesis in older adults (60-75 years of age) by
approximately15%. An abstract based on our clinical trial was
accepted and will be presented at the International Conference on
Frailty & Sarcopenia Research in March
2020 in Toulouse,
France.
- Leveraging results from our human clinical trial at
University of California, Berkeley,
launched MYOS Physician Muscle Health
Formula® at the American Academy of
Anti-Aging Medicine (A4M) Conference in Las Vegas, NV in December 2019.
- Completed randomized, double blind, placebo-controlled
clinical study at Kansas
State University demonstrating that
Fortetropin prevented atrophy of disuse and improved recovery for
dogs after TPLO surgery and presented the results at the North
American Veterinary Conference/VMX in Orlando.
- Established a distribution partnership with
Chewy.com for MYOS' Animal Health
products.
- Launched the MYOS Canine Muscle
Health Formula Vet
Strength nutrition product in order to
strengthen the company's direct-to-vet distribution
channel.
- Obtained U.S. Patent number 10,165,785
related to our advanced manufacturing process for Fortetropin
and filed three additional US and PCT applications.
- Established a marketing partnership for YOLKED® with Carli Lloyd (USWNT) and
Aaron Gordon (Orlando Magic).
- Initiated a randomized, placebo-controlled crossover
study at the Animal Medical Center, New York to study the impact of Fortetropin on
serum myostatin levels in dogs over 24 hours.
- Initiated a randomized, double blind,
placebo-controlled clinical study at Kansas
State University to study the impact of
Fortetropin on quality of life (QOL) and mobility in geriatric
dogs.
- Initiated a randomized, double blind,
placebo-controlled clinical study at
McMaster University to study the
impact of Fortetropin on atrophy of disuse in young
adults.
- Recruited Dante
Carnevale (Learfield IMG College) as the
company's Chief Strategist, added a digital copywriter and expanded
our inside sales force.
- Recruited Albert Ahn,
DVM, an Animal Health Industry Senior Executive
with over 25 years of industry experience to serve as a Strategic
Adviser to MYOS and lead the development of the company's Animal
Health Business
- Added three board members who are firmly committed to
increasing shareholder value and can help management with their
industry experience.
-
- Eric Zaltas
– R&D, process innovation, product launch, and
distribution experience in the nutrition industry at
Nestle and Post Holdings.
- Andrew Ponte
– 20+ years as a senior executive in the pet industry with
leadership roles in sales, marketing and finance at Spectrum Brands
and Central Garden & Pet.
- Christopher
Dewey – a seasoned executive with over
thirty years of experience in finance and investment banking who
co-founded several companies and holds an MBA from the Wharton
School of the University of
Pennsylvania.
CONCLUSION
In 2019 our scientific case for Fortetropin was strengthened
with success in two clinical studies. With this scientific foundation, we
have developed vibrant brands and marketing programs to get our
products into the marketplace in three high growth areas. The
marketplace is embracing our products, our brands are resonating
with consumers, and most importantly our revenues are
growing. We are only in the early stages of this process and
we expect greater results from here.
I sincerely thank all MYOS shareholders and
customers. We took many risks and embraced uncertainty over
the last few years and it is paying off for all stakeholders of
MYOS. Thank you for letting us go there and supporting
us.
Our entire team greatly appreciates the confidence you
have shown in our mission, products, and operations. We will
keep you updated on our progress as developments unfold.
Joseph
Mannello
Chief Executive
Officer
MYOS RENS Technology
About MYOS RENS Technology Inc.
MYOS RENS Technology Inc. (MYOS), "The Muscle
Company®", is a Cedar Knolls,
NJ-based advanced nutrition company that develops and
markets products that improve muscle health and performance. MYOS
is the owner of Fortetropin®, a fertilized egg
yolk-based product manufactured via a proprietary process to retain
and optimize its biological activity. Fortetropin has been
clinically shown to increase muscle size, lean body mass and reduce
muscle atrophy. MYOS believes Fortetropin has the potential to
redefine existing standards of physical health and wellness. For
more information, please visit www.myosrens.com.
About Yolked® and Physician Muscle Health
Formula®
Yolked, an NSF Certified for
Sport® all-natural sports nutrition
product and Physician Muscle Health Formula
for longevity are both designed to work in
conjunction with your protein of choice to help your body utilize
that protein more efficiently. Their key ingredient,
Fortetropin, is made through a patented process that
maintains the vital nutrients of fertilized egg yolks to help build
more lean muscle and decrease muscle loss. For more
information, please visit www.myosrens.com.
About Myos Canine Muscle
Formula®
Myos Canine Muscle Formula
(Regular and Veterinarian Strength) is an advanced
veterinary health supplement to support muscle health in dogs,
featuring Fortetropin as the active ingredient. Fortetropin
is made through a patented process that maintains the vital
nutrients of fertilized egg yolks to help build more lean muscle
and decrease muscle loss. For more information, please visit
www.myospet.com.
Forward-Looking
Statements
Any statements in this
release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including Qurr®, Yolked®, MYOS Canine Muscle
Formula®, Physician Muscle Health Formula® and MYOS
Enteral Nutrition Formula™, the success of our
research and development, the results of the clinical evaluation
of Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate revenue and cash
flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
Investor Relations:
MYOS RENS Technology
Joanne Goodford
Phone: 973-509-0444
Email: jgoodford@myoscorp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-ceo-joseph-mannello-issues-letter-to-shareholders-300984013.html
SOURCE MYOS RENS Technology